$Merck & Co (MRK.US)$'s $11.5 bil bet on Acceleron in 2021 p...
$Merck & Co(MRK.US$'s $11.5 bil bet on Acceleron in 2021 pays off w/ FDA approval of Wenrevair for PAH,
When deal closed in 2021 analysts were projecting peak sales of $2.2 bil for sotatercept (Wenrevair), now estimates are as high as $5-$7.5 bil,
Looks like MRK got a great deal but Wenrevair would still only cover about 20%-25% of Keytruda's $25 bil in rev from LOE in 2028,
MRK's made 4 other big acquisitions since 2021: $680 mil for $HARP, $610 mil for Caraway, $1.3 bil for Imago and the biggest was $10.8 bil for $RXDX last yr,
RXDX is furthest long in dev line w/ IBD drug proj to have peak sales around $2.4 bil,
MRK still has a long way to go to plug the Keytruda gap, successful big bets like Acceleron gives confidence to pursue more M&A deals
When deal closed in 2021 analysts were projecting peak sales of $2.2 bil for sotatercept (Wenrevair), now estimates are as high as $5-$7.5 bil,
Looks like MRK got a great deal but Wenrevair would still only cover about 20%-25% of Keytruda's $25 bil in rev from LOE in 2028,
MRK's made 4 other big acquisitions since 2021: $680 mil for $HARP, $610 mil for Caraway, $1.3 bil for Imago and the biggest was $10.8 bil for $RXDX last yr,
RXDX is furthest long in dev line w/ IBD drug proj to have peak sales around $2.4 bil,
MRK still has a long way to go to plug the Keytruda gap, successful big bets like Acceleron gives confidence to pursue more M&A deals
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
